Showing 301 - 320 results of 65,012 for search '(( 5 ng decrease ) OR ( 5 ((((we decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 0.96s Refine Results
  1. 301

    DataSheet1_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.PDF by Sunil Veeravalli (5074115)

    Published 2022
    “…<p>We previously showed that Fmo5<sup>−/−</sup> mice exhibit a lean phenotype and slower metabolic ageing. …”
  2. 302

    Image1_Reduction of kinesin I heavy chain decreases tau hyperphosphorylation, aggregation, and memory impairment in Alzheimer’s disease and tauopathy models.jpg by Karthikeyan Selvarasu (14004867)

    Published 2022
    “…We also found that the knockdown and knockout (KO) of KIFf5B significantly decreased the tau stability, and overexpression of KIF5B in KIF5B-KO cells significantly increased the expression of phosphorylated and total tau levels. …”
  3. 303
  4. 304
  5. 305

    Image5_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  6. 306

    Participants characteristics. by Sakiko Fukui (387048)

    Published 2025
    “…</p><p>Methods</p><p>Sixty-nine deceased older adults from five special nursing homes were studied over 3.5 years (January 2016 to June 2020). …”
  7. 307
  8. 308
  9. 309
  10. 310
  11. 311
  12. 312

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
  13. 313
  14. 314
  15. 315

    DataSheet2_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Since WNT5A-responsive mechanisms on eMSC are still uncertain, we hypothesize that the WNT ligand–WNT5A works to activate WNT/β-catenin signaling through binding to Frizzled receptors (FZDs) and co-receptor low-density lipoprotein receptor-related protein 5 (LRP5). …”
  16. 316

    DataSheet1_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Since WNT5A-responsive mechanisms on eMSC are still uncertain, we hypothesize that the WNT ligand–WNT5A works to activate WNT/β-catenin signaling through binding to Frizzled receptors (FZDs) and co-receptor low-density lipoprotein receptor-related protein 5 (LRP5). …”
  17. 317

    DataSheet2_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Since WNT5A-responsive mechanisms on eMSC are still uncertain, we hypothesize that the WNT ligand–WNT5A works to activate WNT/β-catenin signaling through binding to Frizzled receptors (FZDs) and co-receptor low-density lipoprotein receptor-related protein 5 (LRP5). …”
  18. 318

    DataSheet1_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Since WNT5A-responsive mechanisms on eMSC are still uncertain, we hypothesize that the WNT ligand–WNT5A works to activate WNT/β-catenin signaling through binding to Frizzled receptors (FZDs) and co-receptor low-density lipoprotein receptor-related protein 5 (LRP5). …”
  19. 319

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”
  20. 320

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”